Bayer's September Crossroads: A Kidney Drug's Ascent Meets the Final Roundup Hurdle

Bayer's Kerendia sales jump 75% to €603M in H1 2026, but September 14 Roundup settlement hearing looms. Analysts mostly bullish.

The calendar at Bayer is beginning to look like a study in contrasts. One date — September 14 — carries the weight of a multi-billion-dollar legal saga that has shadowed the stock for years. Another set of milestones, spread across recent weeks, tells a quieter story of clinical progress and commercial momentum that the market has only partially digested.

Investors weighing the German conglomerate's prospects are now forced to reconcile two very different timelines: the slow-burn potential of a fast-growing kidney medicine and the binary outcome of a court hearing that could finally close the book on its most persistent overhang.

A Drug Finding Its Footing

While the glyphosate litigation has dominated headlines, Bayer has been quietly building a case for Kerendia as a genuine growth engine. The drug, approved for chronic kidney disease in type 2 diabetes patients, generated €603 million in revenue during the first half of 2026 — a 75 percent jump year over year.

The latest catalyst came at the ESC Congress in Munich in late August, where Bayer presented a subgroup analysis from the Phase III FIND-CKD trial. The data suggested Kerendia could also benefit patients with hypertensive nephropathy — kidney damage caused by chronic high blood pressure. That matters beyond the clinical detail: it potentially widens the drug's addressable market at a time when the rest of the pharma segment is struggling to impress.

The timing is hardly coincidental. Bayer's second-quarter results, released in early August, painted a picture of a company growing only modestly at the top line while earnings took a meaningful hit. Group revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to €10.9 billion, but core earnings per share fell 16.7 percent to €0.95, dragged down by a higher tax rate and weaker segment performance.

Wall Street Weighs In

The quarterly report triggered a wave of analyst responses, and the tone was largely supportive. Within the first week of August, four major investment banks reaffirmed their positive stances: Deutsche Bank and UBS both confirmed Buy ratings, while JP Morgan held at Overweight and Goldman Sachs stuck with Buy. The near-unanimous show of confidence suggested the market's biggest houses saw more to like than to worry about in the numbers.

Jefferies struck a more cautious note roughly a week later, issuing a Hold rating on August 10 — the outlier in an otherwise bullish field.

That split between broad optimism and selective skepticism mirrors the company's own position: operationally on track, but still carrying legal baggage that no analyst can fully model away.

The Legal Clock Ticks

The legal picture, meanwhile, has shown signs of progress — though not finality. The U.S. Court of Appeals for the Eighth Circuit rejected a challenge by plaintiffs to the $7.25 billion Roundup settlement, a procedural win that removed one layer of uncertainty. The case remains active in Missouri, where a hearing on final approval of the deal is scheduled for September 14.

Notably, Bayer and plaintiffs' attorneys jointly requested the hearing date, citing the need to process opt-out revocation requests following the Supreme Court's preemption ruling in June. That the two sides are cooperating on logistics suggests a shared interest in seeing the settlement through — but the very existence of opt-out appeals is a reminder that unresolved questions persist even after a favorable Supreme Court decision.

Balance Sheet Relief

On the financial front, Bayer has given itself more breathing room. The capital injection from Apollo Global Management, agreed over the summer, brought €3 billion into the company. As a result, management revised its year-end net financial debt forecast downward from €32–33 billion to €29–30 billion.

That deleveraging trajectory matters for a company whose balance sheet has been a source of investor anxiety. Lower debt reduces the risk profile and gives management more flexibility — even if the core business is not exactly firing on all cylinders.

The Bull and Bear Case

The optimistic scenario for Bayer rests on a simple arithmetic: if Kerendia maintains its growth trajectory while additional indications come through, the pharma segment could gradually shift from liability to asset in the investment narrative. The ESC data on slowing kidney function decline provides the scientific foundation for that story, potentially supporting further label expansions.

Add in the shrinking debt pile and a crop science division that helped support the quarter, and the stock's path toward its 52-week high of €53.86 — currently about ten percent away — becomes more plausible.

The bear case is equally straightforward. Kerendia's 75 percent growth rate, however impressive, starts from a relatively small base in the context of a €40-billion-plus company. The core business is showing genuine weakness in earnings per share, and consumer health is not providing the counterweight investors might hope for. Should Kerendia's momentum stall, or should further label expansions fail to materialize, the pharma segment would lack a credible growth story to offset its structural challenges.

And then there is the September 14 hearing itself. A setback there could quickly overshadow any operational improvement, reviving the legal overhang that has suppressed Bayer's valuation for years.

What to Watch

The stock's recent behavior suggests investors are holding their breath. Shares closed at €48.70 on Tuesday, down 0.7 percent on the day — a muted reaction that fits a pattern of short-term stagnation despite a 32 percent gain since the start of the year.

That gap between the recent pause and the longer-term advance captures Bayer's current predicament: a company that has moved past its most difficult phase but is still waiting for a catalyst that can push it decisively higher. The September 14 hearing offers one such catalyst, for better or worse. The continued clinical development of Kerendia offers another — slower to materialize, but potentially more durable.

For now, the analyst community leans constructive, the balance sheet is improving, and the drug pipeline has at least one credible growth story. Whether that combination proves sufficient depends on how the next several weeks unfold — both in the courtroom and in the clinic.